Drug intelligence / Profile preview

LTB019

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

LTB019 is an oral **leukotriene B4 receptor antagonist** developed for the treatment of respiratory diseases, specifically chronic obstructive pulmonary disease (COPD). Its mechanism of action involves **blocking the leukotriene B4 receptor (LTB4R)**, thereby inhibiting the pro-inflammatory actions of leukotriene B4, which is thought to contribute to neutrophilic airway inflammation. Despite adequate plasma concentrations, a clinical trial in ex-smokers with moderate stable COPD showed that LTB019 had no significant effect on sputum neutrophil counts, cytokine levels (MPO, IL-8, TNF-alpha), or lung function measures, suggesting limited therapeutic efficacy in this population[1][5].

Brand names: LTB019LTB-019LTB 019
Other names: LTB019LTB-019LTB 019

Targets

LTB4R (Leukotriene B4 Receptor 1)

Beyond the preview

Go deeper on LTB019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTB019.

Explore the full profile